BPH Energy Limited

Headquartered in Stirling, Australia, and established in 2001 (initially known as BioPharmica Limited), BPH Energy Limited maintains a diverse investment portfolio spanning biotechnology, oil and gas exploration and development, and the medicinal cannabis sector throughout Australia. The company is actively developing a novel system designed to produce clean hydrogen and conductive carbon, intended for use in commercial battery manufacturing. Additionally, BPH Energy offers a specialized brain anaesthesia response monitoring system, a sophisticated device that assesses the impact of anaesthetic agents on cerebral activity, thereby assisting anaesthetists in maintaining optimal patient sedation levels. Its commitment extends to biomedical research, specifically funding investigations into the HLS5 tumour suppressor gene for liver cancer. In terms of its energy assets, BPH Energy holds complete ownership (100%) of the RL1 oil and gas assets situated in the onshore Bonaparte basin in northern Australia, alongside an 85% stake in the petroleum exploration permit 11 asset located in the offshore Sydney basin.